See more : MFS INC (196A.T) Income Statement Analysis – Financial Results
Complete financial analysis of Luckwel Pharmaceuticals Inc. (LWEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Luckwel Pharmaceuticals Inc., a leading company in the Shell Companies industry within the Financial Services sector.
- Gladstone Commercial Corporation (GOODO) Income Statement Analysis – Financial Results
- Visiber57 Corp. (VCOR) Income Statement Analysis – Financial Results
- Taekwang Industrial Co., Ltd. (003240.KS) Income Statement Analysis – Financial Results
- MCAP Acquisition Corporation (MACQU) Income Statement Analysis – Financial Results
- Genting Hong Kong Limited (0678.HK) Income Statement Analysis – Financial Results
Luckwel Pharmaceuticals Inc. (LWEL)
About Luckwel Pharmaceuticals Inc.
Luckwel Pharmaceuticals Inc. does not have significant operations. It focuses to acquire, develop, manufacture, and market pharmaceutical medications. The company was formerly known as Luckycom Pharmaceuticals Inc. and changed its name to Luckwel Pharmaceuticals Inc. in April 2018. Luckwel Pharmaceuticals Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 5.00 | 295.00 | -1.70K | 44.00 | 950.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 5.00 | 295.00 | -1.70K | 44.00 | 950.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 434.98K | 536.43K | 622.53K | 533.26K | 450.79K | 420.77K | 265.11K | 224.60K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 434.98K | 536.43K | 622.53K | 533.26K | 450.79K | 420.77K | 265.11K | 224.60K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 434.98K | 536.43K | 622.53K | 533.26K | 450.79K | 420.77K | 265.11K | 224.60K |
| Cost & Expenses | 434.98K | 536.43K | 622.53K | 533.26K | 450.79K | 420.77K | 265.11K | 224.60K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -1.04K | 206.30K | 5.00 | -3.83K | -59.92K | 9.17K | 27.50K | 18.33K |
| EBITDA | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 | 0.00 | 0.00 | -185.47K |
| EBITDA Ratio | 0.00% | 0.00% | -12,450,520.00% | -182,063.73% | 30,077.03% | -935,365.91% | -24,911.05% | 0.00% |
| Operating Income | -434.98K | -536.43K | -622.53K | -533.26K | -450.79K | -420.77K | -265.11K | -224.60K |
| Operating Income Ratio | 0.00% | 0.00% | -12,450,620.00% | -180,766.10% | 26,548.29% | -956,300.00% | -27,905.79% | 0.00% |
| Total Other Income/Expenses | -1.04K | -13.40K | 5.00 | -3.83K | 0.00 | -14.31K | 950.00 | 0.00 |
| Income Before Tax | -436.01K | -536.43K | -622.53K | -537.09K | -510.71K | -420.73K | -264.16K | -224.60K |
| Income Before Tax Ratio | 0.00% | 0.00% | -12,450,520.00% | -182,063.73% | 30,077.03% | -956,200.00% | -27,805.79% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00 | 950.00 | 0.00 |
| Net Income | -436.01K | -536.43K | -622.53K | -537.09K | -510.71K | -420.73K | -264.16K | -224.60K |
| Net Income Ratio | 0.00% | 0.00% | -12,450,520.00% | -182,063.73% | 30,077.03% | -956,200.00% | -27,805.79% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| Weighted Avg Shares Out | 143.38M | 143.38M | 132.07M | 18.30M | 17.57M | 14.56M | 10.50M | 10.50M |
| Weighted Avg Shares Out (Dil) | 143.38M | 143.38M | 132.07M | 18.30M | 17.57M | 14.56M | 10.50M | 10.50M |
Source: https://incomestatements.info
Category: Stock Reports